11990713

Source:http://linkedlifedata.com/resource/pubmed/id/11990713

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0123931, umls-concept:C0205282, umls-concept:C0280100, umls-concept:C0920321, umls-concept:C1521725
pubmed:issue	2
pubmed:dateCreated	2002-5-6
pubmed:abstractText	To determine the dose-limiting toxicity, maximum tolerated dose, and potential efficacy of irinotecan in children with refractory malignant solid tumors.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/11990713-11990709
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9505928
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Topoisomerase I Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1077-4114
pubmed:author	pubmed-author:AsamiKeikoK, pubmed-author:KanekoMichioM, pubmed-author:KishimotoTomokoT, pubmed-author:MatsunagaTadashiT, pubmed-author:MimayaJun-ichiJ, pubmed-author:MugishimaHideoH, pubmed-author:SawadaTadashiT, pubmed-author:SuitaSachiyoS, pubmed-author:TsuchidaYoshiakiY, pubmed-author:YagiKeikoK
pubmed:issnType	Print
pubmed:volume	24
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	94-100
pubmed:dateRevised	2011-10-6
pubmed:meshHeading	pubmed-meshheading:11990713-Adolescent, pubmed-meshheading:11990713-Adult, pubmed-meshheading:11990713-Antineoplastic Agents, Phytogenic, pubmed-meshheading:11990713-Bone Marrow Diseases, pubmed-meshheading:11990713-Camptothecin, pubmed-meshheading:11990713-Child, pubmed-meshheading:11990713-Child, Preschool, pubmed-meshheading:11990713-Diarrhea, pubmed-meshheading:11990713-Dose-Response Relationship, Drug, pubmed-meshheading:11990713-Drug-Induced Liver Injury, pubmed-meshheading:11990713-Enzyme Inhibitors, pubmed-meshheading:11990713-Female, pubmed-meshheading:11990713-Humans, pubmed-meshheading:11990713-Infusions, Intravenous, pubmed-meshheading:11990713-Japan, pubmed-meshheading:11990713-Leiomyosarcoma, pubmed-meshheading:11990713-Male, pubmed-meshheading:11990713-Maximum Tolerated Dose, pubmed-meshheading:11990713-Metabolic Clearance Rate, pubmed-meshheading:11990713-Neoplasm Proteins, pubmed-meshheading:11990713-Neuroblastoma, pubmed-meshheading:11990713-Neuroectodermal Tumors, Primitive, pubmed-meshheading:11990713-Topoisomerase I Inhibitors, pubmed-meshheading:11990713-Treatment Outcome
pubmed:year	2002
pubmed:articleTitle	Phase I study of irinotecan in pediatric patients with malignant solid tumors.
pubmed:affiliation	Study Group of Japan for Treatment of Advanced Neuroblastoma, Gunma.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase I